New evidence on the management of Lewy body dementia
- PMID: 31519472
- PMCID: PMC7017451
- DOI: 10.1016/S1474-4422(19)30153-X
New evidence on the management of Lewy body dementia
Abstract
Dementia with Lewy bodies and Parkinson's disease dementia, jointly known as Lewy body dementia, are common neurodegenerative conditions. Patients with Lewy body dementia present with a wide range of cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms. Presentation varies between patients and can vary over time within an individual. Treatments can address one symptom but worsen another, which makes disease management difficult. Symptoms are often managed in isolation and by different specialists, which makes high-quality care difficult to accomplish. Clinical trials and meta-analyses now provide an evidence base for the treatment of cognitive, neuropsychiatric, and motor symptoms in patients with Lewy body dementia. Furthermore, consensus opinion from experts supports the application of treatments for related conditions, such as Parkinson's disease, for the management of common symptoms (eg, autonomic dysfunction) in patients with Lewy body dementia. However, evidence gaps remain and future clinical trials need to focus on the treatment of symptoms specific to patients with Lewy body dementia.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests
J-PT, IGM, DJB, CB, LMA, AJT, and JTO’B report grants from the UK National Institute of Health Research (NIHR) during the conduct of this study. J-PT reports non-financial support from Axovant and personal fees from GE Healthcare, outside the submitted work. IGM reports personal fees from Axovant, Eisai, GE Healthcare, Sumitomo Dainippon Pharma, and Heptares, outside the submitted work. BFB reports personal fees for scientific advisory board membership from the Tau Consortium, grants from GE Healthcare, National Institutes of Health, Mangurian Foundation, and Axovant, outside the submitted work. DW reports personal fees from Acadia, outside the submitted work. JTO’B reports personal fees from TauRx, Axon, GE Healthcare, and Eisai, outside the submitted work.
Figures
Similar articles
-
Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies.Can J Neurol Sci. 2004 Feb;31(1):7-21. doi: 10.1017/s0317167100002791. Can J Neurol Sci. 2004. PMID: 15038467 Review.
-
Dementia with Lewy bodies: Challenges in the diagnosis and management.Aust N Z J Psychiatry. 2019 Apr;53(4):291-303. doi: 10.1177/0004867419835029. Epub 2019 Mar 8. Aust N Z J Psychiatry. 2019. PMID: 30848660 Review.
-
Lewy Body Dementias.Continuum (Minneap Minn). 2019 Feb;25(1):128-146. doi: 10.1212/CON.0000000000000685. Continuum (Minneap Minn). 2019. PMID: 30707190 Review.
-
Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia.Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):435-63. doi: 10.1212/CON.0000000000000309. Continuum (Minneap Minn). 2016. PMID: 27042903 Free PMC article. Review.
-
Altered awareness of cognitive and neuropsychiatric symptoms in Parkinson's disease and Dementia with Lewy Bodies: A systematic review.Int J Geriatr Psychiatry. 2021 Jan;36(1):15-30. doi: 10.1002/gps.5415. Epub 2020 Sep 14. Int J Geriatr Psychiatry. 2021. PMID: 32869379 Review.
Cited by
-
Whole-genome sequencing to identify rare variants in East Asian patients with dementia with Lewy bodies.NPJ Aging. 2024 Nov 21;10(1):52. doi: 10.1038/s41514-024-00180-2. NPJ Aging. 2024. PMID: 39572598 Free PMC article.
-
Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence.Curr Atheroscler Rep. 2024 Nov 9;27(1):2. doi: 10.1007/s11883-024-01255-x. Curr Atheroscler Rep. 2024. PMID: 39520593 Free PMC article. Review.
-
Mitochondrial Dysfunction in Parkinson's Disease: A Contribution to Cognitive Impairment?Int J Mol Sci. 2024 Oct 25;25(21):11490. doi: 10.3390/ijms252111490. Int J Mol Sci. 2024. PMID: 39519043 Free PMC article. Review.
-
Understanding the nature and impact of cognitive fluctuations and sleep disturbances in dementia with Lewy bodies: A qualitative caregiver study.SAGE Open Med. 2024 Oct 9;12:20503121241271827. doi: 10.1177/20503121241271827. eCollection 2024. SAGE Open Med. 2024. PMID: 39398979 Free PMC article.
-
The epigenetic modification of DNA methylation in neurological diseases.Front Immunol. 2024 Sep 23;15:1401962. doi: 10.3389/fimmu.2024.1401962. eCollection 2024. Front Immunol. 2024. PMID: 39376563 Free PMC article. Review.
References
-
- Vann Jones SA, O’Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 2014; 44: 673–83. - PubMed
-
- Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837–44. - PubMed
-
- Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Dis 2007; 22: 1689–707. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
